MON-LB101 Pharmacokinetics of Liothyronine during Thyroid Hormone Therapy Withdrawal

Background Liothyronine (LT3) is a substitute for levothyroxine (LT4) for thyroid cancer patients during the preparation for nuclear medicine procedures, and there is renewed interest in its use in combination with LT4 in patients who do not respond to the standard treatment. This therapy is commonl...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Endocr Soc
Asıl Yazarlar: Celi, Francesco, Wohlford, George, Linderman, Joyce, Smith, Sheila, Yavuz, Sahzene, Pucino, Frank, Van Tassell, Benjamin
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Endocrine Society 2019
Konular:
Thyroid
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6550962/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-LB101
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller